EUVIMEDEUVIMED entdecken
Crossref

Flurbiprofen-infused Electrospun Nanofibers-based Ocular Inserts: A Sustained-Release Platform with Enhanced Tear Pharmacokinetics

Vivek Rajkule, Ganesh Sitap, Kavita Patil, Bhupendra Prajapati, Dipak Bari, Imtiyaz Ansari, Prasad Shinde, Chetan Bhat, Suprit Saoji, CHANDRAKANTSING VIJAYSING PARDESHI

Advanced Pharmaceutical Bulletin · 24.10.2026

DOI: 10.34172/apb.47513 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Pharmaceutical Bulletin, online erschienen am 24.10.2026. Verfasst von Vivek Rajkule und 9 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

This study developed and evaluated flurbiprofen-loaded electrospun ocular inserts fabricated from the polycaprolactone (PCL). The primary objective was to design a prolonged release drug delivery system, specifically using FB-PCL-NFIs, as a novel alternative to existing ocular dosage forms for managing diverse ocular disease conditions viz. conjunctivitis, blepharitis, uveitis, scleritis, or dry eye syndrome.

Methods

The FB-PCL-NFIs were fabricated using monoaxial electrospinning technique and primarily characterized for physicochemical properties, contact angle measurements, diffusion, permeation, tensile strength, and stability analyses. The ocular irritancy of the FB-PCL-NFIs was investigated using isotonicity testing and in ovo Hen’s Egg Test-Chorioallantoic Membrane (HET-CAM) assay.

Results

The prepared FB-PCL-NFIs benefited from the enhanced ocular retention, sustained FB release, enhanced permeation, and improved patient compliance. The in vivo studies confirmed no noticeable signs of irritation suggesting biocompatibility, tolerability, and suitability of the prepared FB-PCL-NFIs for ocular administration. The in vivo ocular pharmacokinetic studies performed in adult male New Zealand White (NZW) rabbits confirmed the prolonged ocular residence of FB-PCL-NFIs compared to Ocuflur® IP.

Conclusion

The findings support further evaluation of the inserts for prolonged ocular delivery of FB-PCL-NFIs as promising therapy for ocular irritation associated with various ocular disease.

Zitieren

APA

Rajkule, V., Sitap, G., Patil, K., Prajapati, B., Bari, D., Ansari, I., Shinde, P., Bhat, C., Saoji, S., & PARDESHI, C. V. (2026). Flurbiprofen-infused Electrospun Nanofibers-based Ocular Inserts: A Sustained-Release Platform with Enhanced Tear Pharmacokinetics. Advanced Pharmaceutical Bulletin. https://doi.org/10.34172/apb.47513

Vancouver

Rajkule V, Sitap G, Patil K, Prajapati B, Bari D, Ansari I, et al. Flurbiprofen-infused Electrospun Nanofibers-based Ocular Inserts: A Sustained-Release Platform with Enhanced Tear Pharmacokinetics. Advanced Pharmaceutical Bulletin. 2026. doi:10.34172/apb.47513

BibTeX
@article{Rajkule2026,
  author = {Rajkule, Vivek and Sitap, Ganesh and Patil, Kavita and Prajapati, Bhupendra and Bari, Dipak and Ansari, Imtiyaz and Shinde, Prasad and Bhat, Chetan and Saoji, Suprit and PARDESHI, CHANDRAKANTSING VIJAYSING},
  title = {Flurbiprofen-infused Electrospun Nanofibers-based Ocular Inserts: A Sustained-Release Platform with Enhanced Tear Pharmacokinetics},
  journal = {Advanced Pharmaceutical Bulletin},
  year = {2026},
  doi = {10.34172/apb.47513}
}
Kostenlos starten →